Other Search Results
Aug 17, 2009 -
- Sally King Benedict is an artist to admire. — Nick Olsen
- Even kids' desks can be cool. — Anh-Minh
- The Black & Spiro website has arrived.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Prognosis
- Diagnosis
- Prevention
- Treatment
- Home Remedies
- Medications
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Ear Infections
Middle ear (otitis media) infections are very common in young children. They include:
- Acute otitis media (AOM) is an inflammation caused by bacteria that travel to the middle ear from fluid trapped in the Eustachian tube. Children with AOM exhibit signs of an ear infection including pain, fever, and tugging at the ear.
- Otitis media with effusion (OME) refers to fluid that accumulates in the middle ear without obvious signs of infection.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Prognosis
- Risk Factors
- Symptoms
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Symptoms
- Causes
- Prognosis
- Risk Factors
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks.
- 0 Comments